This finding suggests the usefulness of a GLP-1R agonist in PNDM characterized by impaired insulin secretion as the main pathophysiology, which is different from that of type 2 diabetes consisting of insulin resistance and impaired insulin secretion. The gene discussed is INS; the disease is type 2 diabetes mellitus.